Neurocrine Biosciences financials
$138.35−1.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788.1M | $451.2M | $161.6M | $15.0M |
| Gross profit | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B | $1.04B | $780.7M | $446.3M | $160.4M | $15.0M |
| Gross margin | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | 99.1% | 98.9% | 99.2% | 100.0% |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M | $163.0M | $72.3M | $36.8M | -$131.4M | -$147.4M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37.0M | $21.1M | -$142.5M | -$141.1M |
| Net margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | −88.2% | −940.6% |
| Diluted EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 |
| EBITDA | $666.6M | $610.1M | $416.1M | $264.6M | $218.7M | $336.1M | $234.0M | $45.6M | -$99.0M | -$145.9M |
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M | $228.5M | $147.0M | $101.4M | -$94.3M | -$106.2M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M | $217.6M | $132.3M | $76.6M | -$101.3M | -$110.3M |
| Diluted shares | 102.5M | 103.7M | 101.0M | 98.9M | 97.9M | 97.8M | 95.7M | 95.4M | 88.1M | 86.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $713.0M | $233.0M | $251.1M | $262.9M | $340.8M | $187.1M |
| Short-term investments | $767.4M | $843.1M | $780.5M | $726.4M | $370.5M | $613.9M |
| Total debt | $0.00 | $0.00 | $170.1M | $169.4M | $335.1M | $317.9M |
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B |
| Total liabilities | $1.38B | $1.13B | $1.02B | $660.9M | $698.5M | $608.5M |
| Shareholders' equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology